Please assess the completion status of the following clinical trial:

Trial Title: 99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with RA based on ACR/EULAR 2010 criteria (score \>=6), or Patients diagnosed with AS based on the ASAS criteria. Patients with RA must have serology assessment performed and documented at the time of enrollment.~* Patient with RA active disease (DAS \> 2,6) and the introduction of a Bi-DMARD should be indicated. RA patients must have been treated with DMARD (methotrexate, leflunomide and sulfasalazine) or combination of these treatments for at least 3 months. Treatment will be pursued while on study.~or RA patients must have been previously treated with Bi-DMARD before initiation of the new Bi-DMARD treatment. The non-response of the previous Bi-DMARD treatment must be documented.~or Patients with AS with insufficiently controlled disease while under NSAID and indication for Bi-DMARD. These patients must be under NSAID for at least 3 months and under the same NSAID for at least 1 month prior to enrollment.~* ≥ 18 years old~* Karnofsky ≥ 80%~* Negative Pregnancy test for women with childbearing potential~* For women with childbearing potential, use of two reliable means of contraception (e.g., hormonal contraceptive, patch, vaginal ring, intrauterine device, associated with other barrier method of contraception such as the use of condoms) , throughout their participation in the study~* Absence of ECG anomaly~* written ICF signed~Exclusion Criteria:~* Pregnancy or lactation~* Liver impairment (ALT, AST or Bilirubin \> 2 ULN) at screening visit or baseline~* Kidney impairment (serum creatinine \> 1.5 mg/dL)~* History of congestive heart failure (NYHA III \& IV)~* History of malignant disease within 5 years~* History of any disease or relevant physical or psychiatric condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment~* Known hypersensitivity to the investigational drug or any of its components~* Participation to another clinical trial within 4 weeks before study inclusion except for patients who have participated or who are currently participating in an interventional study without any study drug administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 99mTc-rhAnnexin V-128, i.v. (Type: EXPERIMENTAL): Patients will receive 2 administrations of the 99mTc-rhAnnexin V-128 medical imaging agent: one at Day 1 and the other at Day 42.

Based on this trial design, predict the completion outcome and termination type (if applicable).